Showing results (381-390 of 414) with videos related to

Sort By:
Pageof 42
Oncogene|September 2, 2018
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancerZachary A Yochum, Jessica Cades, Hailun Wang, et al.
Medicine and Science in Sports and Exercise|May 17, 2017
Individual Variation in Hunger, Energy Intake, and Ghrelin Responses to Acute ExerciseJames A King, Kevin Deighton, David R Broom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
Medicine and Science in Sports and Exercise|September 7, 2019
Fibroblast Growth Factor 21 Mediates the Associations between Exercise, Aging, and Glucose RegulationShuen Yee Lee, Stephen F Burns, Kenneth K C Ng, et al.
Antioxidants (Basel, Switzerland)|March 12, 2020
Pulse Wave Velocity Is Associated with Increased Plasma oxLDL in Ageing but Not with FGF21 and Habitual ExerciseShuen Yee Lee, Stephen F Burns, Kenneth K C Ng, et al.
Molecular and Cellular Biology|February 17, 2005
DR5 knockout mice are compromised in radiation-induced apoptosisNiklas Finnberg, Joshua J Gruber, Peiwen Fei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancerDavid E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Pageof 42